RDEA SEC-arkivering - Ardea Biosciences, Inc.- Årsrapport, fuldmagtserklæring, prospekt

Grundlæggende statistik

CIK

1103390

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Ardea Biosciences, Inc.

SEC Filings (Chronological Order)

Denne side giver en komplet, kronologisk liste over SEC-arkiveringer, eksklusive ejerskabsregistreringer, som vi leverer andre steder.

February 14, 2013	SC 13G/A	RDEA / Ardea Biosciences, Inc. / Visium Asset Management, LP - SCHEDULE 13G (AMENDMENT NO. 6) Passive Investment SC 13G/A 1 d487163dsc13ga.htm SCHEDULE 13G (AMENDMENT NO. 6) SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* Ardea Biosciences, Inc. (Name of Issuer) COMMON STOCK, $0.001 PER SHARE (Title of Class of Securities) 03969P107 (CUSIP Number) December 31, 2012 (Date of Event Which Requires Filing of this Statement) Check
July 2, 2012	15-12B	- 15-12B UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: 3235-0167 Expires: December 31, 2014 Estimated average burden hours per response . . . 1.50 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCH
June 22, 2012	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Termination of a Material Definitive Agreement, Material Modification to Rights of Security Holders, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Completion of Acquisition or Disposition of Assets 8-K 1 d369465d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant To Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of earliest event reported: June 19, 2012 Ardea Biosciences, Inc. (Exact Name Of Registrant as Specified in Charter) Delaware 001-33734 94-3200380 (State or Other Jurisdiction of Incorporation) (Com
June 22, 2012	EX-3.2	AMENDED AND RESTATED ARDEA BIOSCIENCES, INC. a Delaware Corporation TABLE OF CONTENTS Page ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II MEETINGS OF STOCKHOLDERS 1 Section 1. Place of Meeting 1 Section 2. An AMENDED AND RESTATED BYLAWS OF ARDEA BIOSCIENCES, INC. Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ARDEA BIOSCIENCES, INC. a Delaware Corporation TABLE OF CONTENTS Page ARTICLE I OFFICES 1 Section 1. Registered Office 1 Section 2. Other Offices 1 ARTICLE II MEETINGS OF STOCKHOLDERS 1 Section 1. Place of Meeting 1 Section 2. Annual Meetings 1 Section 3. Notice of Meeting 1 Section 4. Stockholder Lis
June 22, 2012	EX-3.1	AMENDED AND RESTATED CERTIFICATE OF INCORPORATION ARDEA BIOSCIENCES, INC. ARTICLE I AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ARDEA BIOSCIENCES, INC. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ARDEA BIOSCIENCES, INC. ARTICLE I NAME The name of the Corporation is Ardea Biosciences, Inc. ARTICLE II REGISTERED OFFICE AND REGISTERED AGENT The registered office of the Corporation in the State of Delaware is located at Corporation Trust Center, 1209 Ora
June 21, 2012	SC 13D/A	RDEA / Ardea Biosciences, Inc. / BAKER JULIAN - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.
June 21, 2012	SC 13D/A	RDEA / Ardea Biosciences, Inc. / GAMCO INVESTORS, INC. ET AL Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4) Ardea Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03969P107 (CUSIP Number) David Goldman GAMCO Investors, Inc. One Corporate Center Rye, New York 10580-1435 (914) 921-5000 (Name, Address and Telephone Number of Person Authorized to Re
June 21, 2012	EX-99.1	JOINT FILING AGREEMENT EX-99.1 2 v316647ex99-1.htm EXHIBIT 99.1 CUSIP No. 03969P107 13D Exhibit 99.1 JOINT FILING AGREEMENT Pursuant to Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that only one statement containing the information required by Schedule 13D need be filed with respect to the ownership by each of the undersigned of the shares of Common Stock of Ardea
June 20, 2012	SC 13D/A	RDEA / Ardea Biosciences, Inc. / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 11 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 11)* ARDEA BIOSCIENCES, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 03969P107 (CUSIP Number) Kevin C. Tang Tang Capital Management, LLC 4747 Executive Drive, Suite 510 San Diego, CA 92121 (858) 200-3830 (Na
June 20, 2012	POS AM	- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-165909 Post-Effective Amendment No. 1 to Form S-3 Registration Statement No. 333-165909 Table of Contents AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JUNE 19, 2012 Registration Statement File No. 333-82934 Registration Statement File No. 333-89840 Registration Statement File No. 333-101633 Registration Statement File No. 333-105288 Registration Statement File No. 333-110197 Registration State
June 20, 2012	POS AM	- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-148765 Post-Effective Amendment No. 1 to Form S-3 Registration Statement No. 333-148765 Table of Contents AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JUNE 19, 2012 Registration Statement File No. 333-82934 Registration Statement File No. 333-89840 Registration Statement File No. 333-101633 Registration Statement File No. 333-105288 Registration Statement File No. 333-110197 Registration State
June 20, 2012	POS AM	- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-82934 Post-Effective Amendment No. 1 to Form S-3 Registration Statement No. 333-82934 Table of Contents AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JUNE 19, 2012 Registration Statement File No. 333-82934 Registration Statement File No. 333-89840 Registration Statement File No. 333-101633 Registration Statement File No. 333-105288 Registration Statement File No. 333-110197 Registration Statem
June 20, 2012	POS AM	- POST-EFFECTIVE AMENDMENT NO. 2 TO FORM S-3 REGISTRATION STATEMENT NO. 333-178746 Post-Effective Amendment No. 2 to Form S-3 Registration Statement No. 333-178746 Table of Contents AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JUNE 19, 2012 Registration Statement File No. 333-82934 Registration Statement File No. 333-89840 Registration Statement File No. 333-101633 Registration Statement File No. 333-105288 Registration Statement File No. 333-110197 Registration State
June 20, 2012	S-8 POS	- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-108096 As filed with the Securities and Exchange Commission on June 19, 2012 Registration Statement No.
June 20, 2012	S-8 POS	- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-117140 As filed with the Securities and Exchange Commission on June 19, 2012 Registration Statement No.
June 20, 2012	S-8 POS	- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-101632 Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-101632 As filed with the Securities and Exchange Commission on June 19, 2012 Registration Statement No. 333-40524 Registration Statement No. 333-65616 Registration Statement No. 333-101632 Registration Statement No. 333-108096 Registration Statement No. 333-117140 Registration Statement No. 333-158521 Registration Statement
June 20, 2012	S-8 POS	- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-65616 Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-65616 As filed with the Securities and Exchange Commission on June 19, 2012 Registration Statement No. 333-40524 Registration Statement No. 333-65616 Registration Statement No. 333-101632 Registration Statement No. 333-108096 Registration Statement No. 333-117140 Registration Statement No. 333-158521 Registration Statement N
June 20, 2012	POS AM	- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-110197 Post-Effective Amendment No. 1 to Form S-3 Registration Statement No. 333-110197 Table of Contents AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JUNE 19, 2012 Registration Statement File No. 333-82934 Registration Statement File No. 333-89840 Registration Statement File No. 333-101633 Registration Statement File No. 333-105288 Registration Statement File No. 333-110197 Registration State
June 20, 2012	POS AM	- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-156708 Post-Effective Amendment No. 1 to Form S-3 Registration Statement No. 333-156708 Table of Contents AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JUNE 19, 2012 Registration Statement File No. 333-82934 Registration Statement File No. 333-89840 Registration Statement File No. 333-101633 Registration Statement File No. 333-105288 Registration Statement File No. 333-110197 Registration State
June 20, 2012	POS AM	- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-153215 Post-Effective Amendment No. 1 to Form S-3 Registration Statement No. 333-153215 Table of Contents AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JUNE 19, 2012 Registration Statement File No. 333-82934 Registration Statement File No. 333-89840 Registration Statement File No. 333-101633 Registration Statement File No. 333-105288 Registration Statement File No. 333-110197 Registration State
June 20, 2012	POS AM	- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-179296 Post-Effective Amendment No. 1 to Form S-3 Registration Statement No. 333-179296 Table of Contents AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JUNE 19, 2012 Registration Statement File No. 333-82934 Registration Statement File No. 333-89840 Registration Statement File No. 333-101633 Registration Statement File No. 333-105288 Registration Statement File No. 333-110197 Registration State
June 20, 2012	POS AM	- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-159279 Post-Effective Amendment No. 1 to Form S-3 Registration Statement No. 333-159279 Table of Contents AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JUNE 19, 2012 Registration Statement File No. 333-82934 Registration Statement File No. 333-89840 Registration Statement File No. 333-101633 Registration Statement File No. 333-105288 Registration Statement File No. 333-110197 Registration State
June 20, 2012	S-8 POS	- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-158521 Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-158521 As filed with the Securities and Exchange Commission on June 19, 2012 Registration Statement No. 333-40524 Registration Statement No. 333-65616 Registration Statement No. 333-101632 Registration Statement No. 333-108096 Registration Statement No. 333-117140 Registration Statement No. 333-158521 Registration Statement
June 20, 2012	S-8 POS	- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-40524 Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-40524 As filed with the Securities and Exchange Commission on June 19, 2012 Registration Statement No. 333-40524 Registration Statement No. 333-65616 Registration Statement No. 333-101632 Registration Statement No. 333-108096 Registration Statement No. 333-117140 Registration Statement No. 333-158521 Registration Statement N
June 20, 2012	POS AM	- POST-EFFECTIVE AMENDMENT NO. 3 TO FORM S-3 REGISTRATION STATEMENT NO. 333-105288 Post-Effective Amendment No. 3 to Form S-3 Registration Statement No. 333-105288 Table of Contents AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JUNE 19, 2012 Registration Statement File No. 333-82934 Registration Statement File No. 333-89840 Registration Statement File No. 333-101633 Registration Statement File No. 333-105288 Registration Statement File No. 333-110197 Registration State
June 20, 2012	S-8 POS	- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-176517 S-8 POS 1 d368776ds8pos.htm POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-8 REGISTRATION STATEMENT NO. 333-176517 As filed with the Securities and Exchange Commission on June 19, 2012 Registration Statement No. 333-40524 Registration Statement No. 333-65616 Registration Statement No. 333-101632 Registration Statement No. 333-108096 Registration Statement No. 333-117140 Registration Statement No. 333-15
June 20, 2012	POS AM	- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-101633 Post-Effective Amendment No. 1 to Form S-3 Registration Statement No. 333-101633 Table of Contents AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JUNE 19, 2012 Registration Statement File No. 333-82934 Registration Statement File No. 333-89840 Registration Statement File No. 333-101633 Registration Statement File No. 333-105288 Registration Statement File No. 333-110197 Registration State
June 20, 2012	POS AM	- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-170105 Post-Effective Amendment No. 1 to Form S-3 Registration Statement No. 333-170105 Table of Contents AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JUNE 19, 2012 Registration Statement File No. 333-82934 Registration Statement File No. 333-89840 Registration Statement File No. 333-101633 Registration Statement File No. 333-105288 Registration Statement File No. 333-110197 Registration State
June 20, 2012	POS AM	- POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 REGISTRATION STATEMENT NO. 333-89840 Post-Effective Amendment No. 1 to Form S-3 Registration Statement No. 333-89840 Table of Contents AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON JUNE 19, 2012 Registration Statement File No. 333-82934 Registration Statement File No. 333-89840 Registration Statement File No. 333-101633 Registration Statement File No. 333-105288 Registration Statement File No. 333-110197 Registration Statem
June 19, 2012	SC 13D/A	RDEA / Ardea Biosciences, Inc. / ASTRAZENECA PLC - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (Amendment No. 1) Under the Securities Exchange Act of 1934 ARDEA BIOSCIENCES, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 03969P107 (CUSIP Number) Adrian Kemp AstraZeneca PLC 2 Kingdom Street, London, England W2 6BD United Kingdom +44 20 7604 8000 with a copy to: Catherin
June 13, 2012	DEFA14A	- DEFINITIVE ADDITIONAL MATERIALS Definitive Additional Materials UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
June 13, 2012	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 13, 2012 ARDEA BIOSCIENCES, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33734 94-3200380 (State or Other Jurisdiction of Incorporation) Commissi
June 13, 2012	EX-99.1	SUPPLEMENT TO THE PROXY STATEMENT FOR THE SPECIAL MEETING OF STOCKHOLDERS To Be Held on June 19, 2012 Proxy Statement Supplement Exhibit 99.1 SUPPLEMENT TO THE PROXY STATEMENT FOR THE SPECIAL MEETING OF STOCKHOLDERS To Be Held on June 19, 2012 This supplement amends and supplements the definitive proxy statement (the “Proxy Statement”) initially filed with the U.S. Securities and Exchange Commission on May 21, 2012 by Ardea Biosciences, Inc. (“we”, “us”, “our”, “Ardea” or the “Company”) for a spec
June 11, 2012	SC 13G/A	RDEA / Ardea Biosciences, Inc. / WELLINGTON MANAGEMENT GROUP LLP - DISCLOSURE DOCUMENT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Ardea Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03969P107 (CUSIP Number) May 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sche
June 5, 2012	8-K	Financial Statements and Exhibits, Other Events, Submission of Matters to a Vote of Security Holders - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2012 Ardea Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-33734 94-3200380 (State or other jurisdiction of incorporation) (Commis
June 5, 2012	EX-99.1	Ardea Biosciences Announces Expiration of HSR Waiting Period in Connection with Proposed Merger Exhibit 99.1 Ardea Biosciences Announces Expiration of HSR Waiting Period in Connection with Proposed Merger SAN DIEGO, CA June 5, 2012 - Ardea Biosciences, Inc. (Nasdaq: RDEA) (“Ardea”), a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, today announced the expiration of the waiting period under the Hart-Scott Rodino Antitrust
June 5, 2012	DEFA14A	- FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 31, 2012 Ardea Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-33734 94-3200380 (State or other jurisdiction of incorporation) (Commis
June 5, 2012	EX-99.1	Ardea Biosciences Announces Expiration of HSR Waiting Period in Connection with Proposed Merger Press release Exhibit 99.1 Ardea Biosciences Announces Expiration of HSR Waiting Period in Connection with Proposed Merger SAN DIEGO, CA June 5, 2012 - Ardea Biosciences, Inc. (Nasdaq: RDEA) (“Ardea”), a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, today announced the expiration of the waiting period under the Hart-Scott Rod
May 30, 2012	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - LIVE FILING Ardea Biosciences, Inc. (Form: 8-K) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 30, 2012 Ardea Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33734 94-3200380 (State or other jurisdict
May 30, 2012	DEFA14A	- DEFINITIVE ADDITIONAL MATERIALS Definitive Additional Materials UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 30, 2012	EX-99.1	Ardea Biosciences Earns Milestone from Bayer HealthCare Contact: John Beck Ardea Biosciences, Inc. (858) 652-6523 [email protected] Ardea Biosciences Earns Milestone from Bayer HealthCare SAN DIEGO, May 30, 2012 — Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that it has earned a $7.5 million milestone from Bayer HealthCare (Bayer) under the terms of their April 2009 global license agreement to develop and commercialize Ardea’s mitogen-activa
May 30, 2012	SC 13D/A	RDEA / Ardea Biosciences, Inc. / GAMCO INVESTORS, INC. ET AL Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3) Ardea Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03969P107 (CUSIP Number) David Goldman GAMCO Investors, Inc. One Corporate Center Rye, New York 10580-1435 (914) 921-5000 (Name, Address and Telephone Number of Person Authorized to Re
May 21, 2012	DEFM14A	- DEFINITIVE PROXY STATEMENT Definitive Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 10, 2012	PREM14A	- PRELIMINARY SPECIAL PROXY STATEMENT Preliminary Special Proxy Statement Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 7, 2012	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - LIVE FILING Ardea Biosciences, Inc. (Form: 8-K) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 7, 2012 Ardea Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33734 94-3200380 (State or other jurisdicti
May 7, 2012	DEFA14A	- SOLICITING MATERIAL Soliciting Material UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 7, 2012	10-Q	Quarterly Report - FORM 10-Q Form 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2012 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-33734 ARDEA BIOSCIENCES, INC.
May 7, 2012	EX-99.1	Ardea Biosciences Announces First Quarter 2012 Financial Results EX-99.1 2 exhibit1.htm EX-99.1 Contact: John Beck Ardea Biosciences, Inc. (858) 652-6523 [email protected] Ardea Biosciences Announces First Quarter 2012 Financial Results SAN DIEGO, May 7, 2012 — Ardea Biosciences, Inc. (Nasdaq: RDEA), a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, today announced first quarter 2012 financ
May 3, 2012	SC 13D/A	RDEA / Ardea Biosciences, Inc. / GAMCO INVESTORS, INC. ET AL Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2) Ardea Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03969P107 (CUSIP Number) David Goldman GAMCO Investors, Inc. One Corporate Center Rye, New York 10580-1435 (914) 921-5000 (Name, Address and Telephone Number of Person Authorized to Re
May 2, 2012	SC 13D/A	RDEA / Ardea Biosciences, Inc. / GAMCO INVESTORS, INC. ET AL Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) Ardea Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03969P107 (CUSIP Number) David Goldman GAMCO Investors, Inc. One Corporate Center Rye, New York 10580-1435 (914) 921-5000 (Name, Address and Telephone Number of Person Authorized to Re
May 1, 2012	EX-3	JOINT FILING AGREEMENT EX-3 2 a12-109311ex3.htm EX-3 EXHIBIT 3 JOINT FILING AGREEMENT The undersigned, being duly authorized thereunto, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule 13D and any amendments thereto jointly on behalf of each
May 1, 2012	SC 13D	RDEA / Ardea Biosciences, Inc. / ASTRAZENECA PLC - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 ARDEA BIOSCIENCES, INC. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 03969P107 (CUSIP Number) Adrian Kemp AstraZeneca PLC 2 Kingdom Street, London, England W2 6BD United Kingdom +44 20 7604 8000 with a copy to: Catherine J. Dargan, Esq. St
April 26, 2012	SC 13D	RDEA / Ardea Biosciences, Inc. / GAMCO INVESTORS, INC. ET AL Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Ardea Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03969P107 (CUSIP Number) David Goldman GAMCO Investors, Inc. One Corporate Center Rye, New York 10580-1435 (914) 921-5000 (Name, Address and Telephone Number of Person Authorized to Receive Notices and
April 25, 2012	EX-99.1	VOTING AGREEMENT EXHIBIT 99.1 VOTING AGREEMENT This Voting Agreement (this “Agreement”) is made and entered into as of April 21, 2012 by and among Zeneca Inc. (“Parent”) and the undersigned stockholder (the “Stockholder”) of Ardea BioSciences, Inc., a Delaware corporation (the “Company”). Recitals Whereas, concurrently with the execution of this Agreement, Parent, QAM Corp., a Delaware corporation and wholly owned
April 25, 2012	SC 13D/A	RDEA / Ardea Biosciences, Inc. / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 10 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 10)* ARDEA BIOSCIENCES, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 03969P107 (CUSIP Number) Kevin C. Tang Tang Capital Management, LLC 4747 Executive Drive, Suite 510 San Diego, CA 92121 (858) 200-3830 (Na
April 24, 2012	EX-99.1	ASTRAZENECA TO ACQUIRE ARDEA BIOSCIENCES FOR $1.26 BILLION INCLUDING LEAD PRODUCT LESINURAD IN PHASE III DEVELOPMENT FOR EX-99.1 4 d339523dex991.htm PRESS RELEASE Exhibit 99.1 ASTRAZENECA TO ACQUIRE ARDEA BIOSCIENCES FOR $1.26 BILLION INCLUDING LEAD PRODUCT LESINURAD IN PHASE III DEVELOPMENT FOR GOUT SAN DIEGO, April 23, 2012 — AstraZeneca and Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that they have entered into a definitive merger agreement, pursuant to which AstraZeneca will acquire Ardea, a San Diego
April 24, 2012	EX-2.1	AGREEMENT AND PLAN OF MERGER ZENECA INC., a Delaware corporation, QAM CORP., a Delaware corporation, and ARDEA BIOSCIENCES, INC. a Delaware corporation Dated as of April 21, 2012 TABLE OF CONTENTS Page(s) ARTICLE I. DESCRIPTION OF TRANSACTION 1 1.1 M EX-2.1 2 d339523dex21.htm AGREEMENT AND PLAN OF MERGER Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among: ZENECA INC., a Delaware corporation, QAM CORP., a Delaware corporation, and ARDEA BIOSCIENCES, INC. a Delaware corporation Dated as of April 21, 2012 TABLE OF CONTENTS Page(s) ARTICLE I. DESCRIPTION OF TRANSACTION 1 1.1 Merger of Merger Sub into the Company 1 1.2 Effect of the Merger 1 1.3 Closin
April 24, 2012	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 21, 2012 ARDEA BIOSCIENCES, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33734 94-3200380 (State or Other Jurisdiction of Incorporation) Commission File
April 24, 2012	EX-2.1	AGREEMENT AND PLAN OF MERGER ZENECA INC., a Delaware corporation, QAM CORP., a Delaware corporation, and ARDEA BIOSCIENCES, INC. a Delaware corporation Dated as of April 21, 2012 TABLE OF CONTENTS Page(s) ARTICLE I. DESCRIPTION OF TRANSACTION 1 1.1 M Exhibit 2.1 AGREEMENT AND PLAN OF MERGER among: ZENECA INC., a Delaware corporation, QAM CORP., a Delaware corporation, and ARDEA BIOSCIENCES, INC. a Delaware corporation Dated as of April 21, 2012 TABLE OF CONTENTS Page(s) ARTICLE I. DESCRIPTION OF TRANSACTION 1 1.1 Merger of Merger Sub into the Company 1 1.2 Effect of the Merger 1 1.3 Closing; Effective Time 1 1.4 Certificate of Incorporation; B
April 24, 2012	EX-99.1	ASTRAZENECA TO ACQUIRE ARDEA BIOSCIENCES FOR $1.26 BILLION INCLUDING LEAD PRODUCT LESINURAD IN PHASE III DEVELOPMENT FOR Press release Exhibit 99.1 ASTRAZENECA TO ACQUIRE ARDEA BIOSCIENCES FOR $1.26 BILLION INCLUDING LEAD PRODUCT LESINURAD IN PHASE III DEVELOPMENT FOR GOUT SAN DIEGO, April 23, 2012 — AstraZeneca and Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that they have entered into a definitive merger agreement, pursuant to which AstraZeneca will acquire Ardea, a San Diego, California-based biotechno
April 24, 2012	EX-10.1	VOTING AGREEMENT Form of Voting Agreement Exhibit 10.1 VOTING AGREEMENT This VOTING AGREEMENT (this “Agreement”) is made and entered into as of April 21, 2012 by and among Zeneca Inc. (“Parent”) and the undersigned stockholder (the “Stockholder”) of Ardea BioSciences, Inc., a Delaware corporation (the “Company”). RECITALS WHEREAS, concurrently with the execution of this Agreement, Parent, QAM Corp., a Delaware cor
April 24, 2012	DEFA14A	- FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): April 21, 2012 ARDEA BIOSCIENCES, INC. (Exact Name of Registrant as Specified in Charter) Delaware 001-33734 94-3200380 (State or Other Jurisdiction of Incorporation) Commission File
April 24, 2012	EX-10.1	VOTING AGREEMENT Form of Voting Agreement Exhibit 10.1 VOTING AGREEMENT This VOTING AGREEMENT (this “Agreement”) is made and entered into as of April 21, 2012 by and among Zeneca Inc. (“Parent”) and the undersigned stockholder (the “Stockholder”) of Ardea BioSciences, Inc., a Delaware corporation (the “Company”). RECITALS WHEREAS, concurrently with the execution of this Agreement, Parent, QAM Corp., a Delaware cor
April 23, 2012	SC 13D/A	RDEA / Ardea Biosciences, Inc. / BAKER JULIAN - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.
April 23, 2012	DEFA14A	- SOLICITING MATERIAL Soliciting Material UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 23, 2012	EX-99	VOTING AGREEMENT VOTING AGREEMENT This Voting Agreement (this “Agreement”) is made and entered into as of April 21, 2012 by and among Zeneca Inc.
April 23, 2012	DEFA14A	- SOLICITING MATERIAL Soliciting Material UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 10, 2012	DEF 14A	- DEF 14A DEF 14A SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Definitive Proxy Statement ¨ Definitive Additional Materials ¨ Soliciting Material Pursuant to § 240.
April 2, 2012	EX-99.1	Summary Description of Ardea Biosciences, Inc. 2012 Executive Bonus Plan As of April 2, 2012 Summary Description of Ardea Biosciences, Inc. 2012 Executive Bonus Plan As of April 2, 2012 Eligibility: Generally, employees of Ardea Biosciences, Inc. with a title of Vice President or above are eligible to participate in the 2012 Executive Bonus Plan (the “Plan”). Participants must be employed with Ardea Biosciences, Inc. on the day that bonuses are paid in order to be eligible for a bonus. Bo
April 2, 2012	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 27, 2012 Ardea Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33734 94-3200380 (State or other jurisdiction (Commission (I.R.S. Employer o
March 9, 2012	EX-99.1	Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2011 Financial Results EX-99.1 2 exhibit1.htm EX-99.1 Contact: John Beck Ardea Biosciences, Inc. (858) 652-6523 [email protected] Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2011 Financial Results SAN DIEGO, March 9, 2012 — Ardea Biosciences, Inc. (Nasdaq: RDEA), a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious
March 9, 2012	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition 8-K 1 htm44476.htm LIVE FILING UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): March 9, 2012 Ardea Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33734 94-3200380 (State or other jurisdiction
March 9, 2012	10-K	Annual Report - FORM 10-K Form 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
February 10, 2012	SC 13G/A	RDEA / Ardea Biosciences, Inc. / Visium Asset Management, LP - AMENDMENT NO.4 Passive Investment Amendment No.4 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.4)* Ardea Biosciences (Name of Issuer) COMMON STOCK, $.001 PER SHARE (Title of Class of Securities) 03969P107 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to
February 10, 2012	SC 13G/A	RDEA / Ardea Biosciences, Inc. / Visium Asset Management, LP - AMENDMENT NO. 5 Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 5)* Ardea Biosciences (Name of Issuer) COMMON STOCK, $.001 PER SHARE (Title of Class of Securities) 03969P107 (CUSIP Number) February 1, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Sch
February 6, 2012	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 1, 2012 Ardea Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-33734 94-3200380 (State or other jurisdiction of incorporation) (Commission
February 6, 2012	EX-99.2	ARDEA BIOSCIENCES PRICES PUBLIC OFFERING OF COMMON STOCK Exhibit 99.2 ARDEA BIOSCIENCES PRICES PUBLIC OFFERING OF COMMON STOCK SAN DIEGO—February 1, 2012—Ardea Biosciences, Inc. (NASDAQ: RDEA) today announced the pricing of an underwritten public offering of 8,500,000 shares of its common stock, offered at a price to the public of $17.00 per share. The gross proceeds to Ardea from this offering are expected to be $144.5 million, before deducting underwr
February 6, 2012	EX-99.3	ARDEA BIOSCIENCES ANNOUNCES EXERCISE IN FULL OF OVER-ALLOTMENT OPTION AND COMPLETION OF PUBLIC OFFERING OF COMMON STOCK EX-99.3 6 d292037dex993.htm PRESS RELEASE DATED FEBRUARY 6, 2012 Exhibit 99.3 ARDEA BIOSCIENCES ANNOUNCES EXERCISE IN FULL OF OVER-ALLOTMENT OPTION AND COMPLETION OF PUBLIC OFFERING OF COMMON STOCK SAN DIEGO—February 6, 2012—Ardea Biosciences, Inc. (NASDAQ: RDEA) today announced the completion of an underwritten public offering of 9,775,000 shares of its common stock, including 1,275,000 shares so
February 6, 2012	SC 13D/A	RDEA / Ardea Biosciences, Inc. / BAKER JULIAN - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.
February 6, 2012	EX-99.1	ARDEA BIOSCIENCES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK EX-99.1 4 d292037dex991.htm PRESS RELEASE DATED JANUARY 31, 2012 Exhibit 99.1 ARDEA BIOSCIENCES ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK SAN DIEGO—January 31, 2012—Ardea Biosciences, Inc. (NASDAQ: RDEA) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an underwritten public offering. There can be no assurance as to w
February 6, 2012	EX-1.1	8,500,000 Shares ARDEA BIOSCIENCES, INC. Common Stock ($0.001 par value per Share) UNDERWRITING AGREEMENT EX-1.1 2 d292037dex11.htm UNDERWRITING AGREEMENT Exhibit 1.1 EXECUTION VERSION 8,500,000 Shares ARDEA BIOSCIENCES, INC. Common Stock ($0.001 par value per Share) UNDERWRITING AGREEMENT February 1, 2012 Jefferies & Company, Inc. as Representative of the several Underwriters c/o Jefferies & Company, Inc. 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Introductory. Ardea Bioscience
February 3, 2012	SC 13D/A	RDEA / Ardea Biosciences, Inc. / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 9 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 9)* ARDEA BIOSCIENCES, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 03969P107 (CUSIP Number) Kevin C. Tang Tang Capital Management, LLC 4747 Executive Drive, Suite 510 San Diego, CA 92121 (858) 200-3830 (Nam
February 3, 2012	424B5	8,500,000 Shares Table of Contents Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-178746 PROSPECTUS SUPPLEMENT (to Prospectus dated January 12, 2012) 8,500,000 Shares Common Stock We are offering 8,500,000 shares of our common stock. Our common stock is listed on The NASDAQ Global Select Market under the symbol “RDEA”. On January 31, 2012, the last reported sale price of our common stock on The NA
February 1, 2012	S-3MEF	- FORM S-3 MEF Form S-3 MEF As filed with the Securities and Exchange Commission on February 1, 2012 Registration No.
January 31, 2012	424B5	Shares Common Stock Preliminary Prospectus Supplement Table of Contents The information in this preliminary prospectus supplement is not complete and may be changed.
January 31, 2012	8-K	Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 31, 2012 Ardea Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-33734 94-3200380 (State or other jurisdiction of incorporation) (Commission
January 12, 2012	424B3	$150,000,000 Ardea Biosciences, Inc. Common Stock Preferred Stock Debt Securities Prospectus Table of Contents This filing is made pursuant to Rule 424(b)(3) under the Securities Act of 1933 in connection with Registration No.
January 10, 2012	SC 13G	RDEA / Ardea Biosciences, Inc. / WELLINGTON MANAGEMENT GROUP LLP - DISCLOSURE DOCUMENT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Ardea Biosciences, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 03969P107 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this
January 10, 2012	CORRESP	- Acceleration Request January 10, 2012 VIA EDGAR AND FACSIMILE Jeffrey Riedler Division of Corporation Finance U.
January 9, 2012	8-K	Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K Form 8-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
January 9, 2012	EX-99.1	Ardea Biosciences EX-99.1 2 d279451dex991.htm ARDEA BIOSCIENCES, INC. PRESENTATION MATERIALS Ardea Biosciences Company Update January 9, 2012 Exhibit 99.1 Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties,
January 5, 2012	COVER	- Comment Letter to SEC VIA U.S. MAIL AND EDGAR January 5, 2012 Jeffrey Riedler Assistant Director Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Ardea Biosciences, Inc. Registration Statement on Form S-3 Filed December 23, 2011 File No. 333-178746 Dear Mr. Riedler: On behalf of Ardea Biosciences, Inc. (“Ardea” or the “Company”), I co
January 5, 2012	S-3/A	- AMENDMENT NO. 1 TO FORM S-3 Table of Contents As filed with the Securities and Exchange Commission on January 5, 2012 Registration No.
December 23, 2011	EX-12.1	Statement Regarding Computation of Ratios of Earnings to Fixed Charges and Ratio of Combined Fixed Charges and Preference Dividends to Earnings Year ended Nine months 2006 2007 2008 2009 2010 9/30/11 Earnings: Loss before income taxes $ (2,746 ) $ (2 Statement Regarding Computation of Ratios EXHIBIT 12.1 Statement Regarding Computation of Ratios of Earnings to Fixed Charges and Ratio of Combined Fixed Charges and Preference Dividends to Earnings Year ended Nine months 2006 2007 2008 2009 2010 9/30/11 Earnings: Loss before income taxes $ (2,746 ) $ (27,574 ) $ (56,475 ) $ (29,951 ) $ (41,143 ) $ (55,824 ) Add: fixed charges — — (215 ) (1,323 )
December 23, 2011	EX-4.5	ARDEA BIOSCIENCES, INC. FORM OF SUBORDINATED DEBT INDENTURE TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Desi EXHIBIT 4.5 ARDEA BIOSCIENCES, INC. AND [TRUSTEE], TRUSTEE FORM OF SUBORDINATED DEBT INDENTURE TABLE OF CONTENTS PAGE ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation and Terms of Securities 4 Section 2.02 Form of Securities and Trustee’s Certificate 6 Section 2.03 Denomina
December 23, 2011	EX-4.10	ARDEA BIOSCIENCES, INC. , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT ARDEA BIOSCIENCES, INC. DEBT SECURITIES WARRANT AGREEMENT EXHIBIT 4.10 ARDEA BIOSCIENCES, INC. and , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT ARDEA BIOSCIENCES, INC. DEBT SECURITIES WARRANT AGREEMENT DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of between ARDEA BIOSCIENCES, INC., a Delaware corporation (the “Company”) and , a [corporation] [national banking association] organized and existing under the laws of and havi
December 23, 2011	EX-4.9	ARDEA BIOSCIENCES, INC. , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT ARDEA BIOSCIENCES, INC. PREFERRED STOCK WARRANT AGREEMENT EXHIBIT 4.9 ARDEA BIOSCIENCES, INC. and , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT ARDEA BIOSCIENCES, INC. PREFERRED STOCK WARRANT AGREEMENT PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of between ARDEA BIOSCIENCES, INC., a Delaware corporation (the “Company”) and , a [corporation] [national banking association] organized and existing under the laws of and havin
December 23, 2011	EX-4.4	ARDEA BIOSCIENCES, INC. FORM OF SENIOR DEBT INDENTURE TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions Of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designatio EX-4.4 2 d267697dex44.htm FORM OF SENIOR DEBT INDENTURE EXHIBIT 4.4 ARDEA BIOSCIENCES, INC. ISSUER AND [TRUSTEE], TRUSTEE FORM OF SENIOR DEBT INDENTURE TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 Section 1.01 Definitions Of Terms 1 ARTICLE 2 ISSUE, DESCRIPTION, TERMS, EXECUTION, REGISTRATION AND EXCHANGE OF SECURITIES 4 Section 2.01 Designation And Terms Of Securities 4 Section 2.02 Form Of Sec
December 23, 2011	EX-4.8	ARDEA BIOSCIENCES, INC. , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT ARDEA BIOSCIENCES, INC. COMMON STOCK WARRANT AGREEMENT EXHIBIT 4.8 ARDEA BIOSCIENCES, INC. and , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT ARDEA BIOSCIENCES, INC. COMMON STOCK WARRANT AGREEMENT COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of between ARDEA BIOSCIENCES, INC., a Delaware corporation (the “Company”) and, a [corporation] [national banking association] organized and existing under the laws of and having a corpor
December 23, 2011	S-3	As filed with the Securities and Exchange Commission on December 23, 2011 Table of Contents As filed with the Securities and Exchange Commission on December 23, 2011 Registration No.
December 22, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Ardea Biosciences, Inc. (Form: 8-K) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 16, 2011 Ardea Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33734 94-3200380 (State or other juri
December 19, 2011	EX-99.1	Ardea Biosciences Initiates Phase 3 Clinical Development Program for Lesinurad EX-99.1 Contact: John Beck Ardea Biosciences, Inc. (858) 652-6523 [email protected] Ardea Biosciences Initiates Phase 3 Clinical Development Program for Lesinurad SAN DIEGO, December 19, 2011 — Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that it has initiated the first of four planned Phase 3 clinical trials in its development program for lesinurad, the Company’s lead product candidate
December 19, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Ardea Biosciences, Inc. (Form: 8-K) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): December 19, 2011 Ardea Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33734 94-3200380 (State or other juri
November 7, 2011	EX-99.1	Ardea Biosciences Provides Additional Positive Clinical Results for Lesinurad and Initial Clinical Results for RDEA3170 at the 2011 ACR/ARHP Annual Scientific 90% Response Rate at 44 Weeks for Lesinurad/Allopurinol Combination in Ongoing Extension Pe Exhibit 99.1 Contact: John Beck Ardea Biosciences, Inc. (858) 652-6523 [email protected] Ardea Biosciences Provides Additional Positive Clinical Results for Lesinurad and Initial Clinical Results for RDEA3170 at the 2011 ACR/ARHP Annual Scientific Meeting 90% Response Rate at 44 Weeks for Lesinurad/Allopurinol Combination in Ongoing Extension Period of Phase 2b Study CHICAGO, November 7, 2011 — A
November 7, 2011	EX-99.2	Ardea Biosciences Ardea Biosciences, Inc. presentation materials Ardea Biosciences Company Update November 7, 2011 Exhibit 99.2 2 Safe Harbor Statement Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, act
November 7, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2011 Ardea Bioscience Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2011 Ardea Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-33734 94-3200380 (State or other jurisdiction of incorporation) (Co
November 4, 2011	EX-99.1	Ardea Biosciences Reports Recent Accomplishments, Important Upcoming Events and Third Quarter 2011 Financial Results Contact: John Beck Ardea Biosciences, Inc. (858) 652-6523 [email protected] Ardea Biosciences Reports Recent Accomplishments, Important Upcoming Events and Third Quarter 2011 Financial Results SAN DIEGO, November 4, 2011 — Ardea Biosciences, Inc. (Nasdaq: RDEA), a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, today reported
November 4, 2011	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2011 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-33734 ARDEA BIOSCIENCES, INC.
November 4, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Ardea Biosciences, Inc. (Form: 8-K) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): November 4, 2011 Ardea Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33734 94-3200380 (State or other juris
October 3, 2011	CORRESP	VIA U.S. MAIL AND EDGAR Correspondence VIA U.S. MAIL AND EDGAR October 3, 2011 James Rosenberg Senior Assistant Chief Accountant Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Ardea Biosciences, Inc. Annual Report on Form 10-K for the year ended December 31, 2010 Filed March 11, 2011 File No. 001-33734 Dear Mr. Rosenberg: On behalf of Ardea Biosciences, In
September 12, 2011	CORRESP	VIA U.S. MAIL AND EDGAR Correspondence VIA U.S. MAIL AND EDGAR September 12, 2011 James Rosenberg Senior Assistant Chief Accountant Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Ardea Biosciences, Inc. Annual Report on Form 10-K for the year ended December 31, 2010 Filed March 11, 2011 File No. 001-33734 Dear Mr. Rosenberg: On behalf of Ardea Biosciences,
September 7, 2011	8-K	Regulation FD Disclosure, Financial Statements and Exhibits Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2011 Ardea Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-33734 94-3200380 (State or other jurisdiction of incorpor
September 7, 2011	EX-99.2	in gout patients otherwise eligible for the following Phase 3 studies: Ardea Biosciences, Inc. presentation materials Long-term Allopurinol Safety Trial (LASSO) – open-label interventional studies of allopurinol in gout patients otherwise eligible for the following Phase 3 studies: Combination Study of Lesinurad in Allopurinol Standard of Care Inadequate Responders (CLEAR #1) – randomized, placebo-controlled trial of lesinurad added to allopurinol in patients not rea
September 7, 2011	EX-99.1	Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad Press release Exhibit 99.1 Contact: John Beck Ardea Biosciences, Inc. (858) 652-6523 [email protected] Ardea Biosciences Announces Positive End-of-Phase 2 Meetings with FDA for Lesinurad SAN DIEGO, September 7, 2011 — Ardea Biosciences, Inc. (Nasdaq: RDEA) announced today that it has completed formal End-of-Phase 2 meetings with the U.S. Food and Drug Administration (FDA) and successfully reached
August 26, 2011	S-8	As filed with the Securities and Exchange Commission on August 26, 2011 As filed with the Securities and Exchange Commission on August 26, 2011 Registration No.
August 5, 2011	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q 10-Q 1 a59144e10vq.htm FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2011 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period f
August 5, 2011	EX-99.1	Ardea Biosciences Reports Recent Accomplishments and Second Quarter 2011 Financial Results EX-99.1 Contact: John Beck Ardea Biosciences, Inc. (858) 652-6523 [email protected] Ardea Biosciences Reports Recent Accomplishments and Second Quarter 2011 Financial Results SAN DIEGO, August 5, 2011 — Ardea Biosciences, Inc. (Nasdaq: RDEA), a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, today reported recent accomplishmen
August 5, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Ardea Biosciences, Inc. (Form: 8-K) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): August 5, 2011 Ardea Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33734 94-3200380 (State or other jurisdi
August 2, 2011	CORRESP	VIA U.S. MAIL AND EDGAR Correspondence Letter VIA U.S. MAIL AND EDGAR August 2, 2011 James Rosenberg Senior Assistant Chief Accountant Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Ardea Biosciences, Inc. Form 10-K for the year ended December 31, 2010 Filed March 11, 2011 File No. 001-33734 Dear Mr. Rosenberg: On behalf of Ardea Biosciences, Inc. (“Ardea”
May 25, 2011	EX-99.2	Ardea Biosciences Provides Additional Results from a Phase 2b Study of Lesinurad in Combination with Allopurinol at the Annual European Congress of Rheumatology Adding Lesinurad to Allopurinol Produced a 91% Response Rate at 28 Weeks in the Extension exv99w2 Exhibit 99.2 Contact: John Beck Ardea Biosciences, Inc. (858) 652-6523 [email protected] Ardea Biosciences Provides Additional Results from a Phase 2b Study of Lesinurad in Combination with Allopurinol at the Annual European Congress of Rheumatology Adding Lesinurad to Allopurinol Produced a 91% Response Rate at 28 Weeks in the Extension Period in Patients Who Failed to Respond to Allopur
May 25, 2011	EX-99.3	Lesinurad (RDEA594), A Novel Oral Uricosuric Agent, in Combination with Febuxostat Shows Significant Additive Urate Lowering Effects in Gout Subjects with 100% Response Achieved for All Combination Dose Regimens R. Fleischmann1, Z. Shen2, L. Yeh2, B. exv99w3 Exhibit 99.3 EFFICACY AND SAFETY OF LESINURAD (RDEA594), A NOVEL URICOSURIC AGENT, GIVEN IN COMBINATION WITH ALLOPURINOL IN ALLOPURINOL-REFRACTORY GOUT PATIENTS: RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, PHASE 2B STUDY F. Perez-Ruiz, J. Sundy, E. Krishnan, V. Hingorani, J. Welp, M. Suster, K. Manhard, Z. Shen, L. Yeh, B. Quart. Annual European Congress of Rheumatology EULAR 201125-28
May 25, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2011 Ardea Biosciences, I e8vk UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2011 Ardea Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-33734 94-3200380 (State or other jurisdiction (Commission (IRS Employer of
May 25, 2011	EX-99.1	Summary Description of Ardea Biosciences, Inc. 2011 Executive Bonus Plan As of May 19, 2011 Exhibit 99.1 Summary Description of Ardea Biosciences, Inc. 2011 Executive Bonus Plan As of May 19, 2011 Eligibility: Generally, employees of Ardea Biosciences, Inc. with a title of Vice President or above are eligible to participate in the 2011 Executive Bonus Plan (the “Plan”). Participants must be employed with Ardea Biosciences, Inc. on the day that bonuses are paid in order to be eligible for
May 9, 2011	EX-99.1	Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results Contact: John Beck Ardea Biosciences, Inc. (858) 652-6523 [email protected] Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2011 Financial Results SAN DIEGO, May 9, 2011 — Ardea Biosciences, Inc. (Nasdaq: RDEA), a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, today reported recent accomplishments
May 9, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Ardea Biosciences, Inc. (Form: 8-K) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest Event Reported): May 9, 2011 Ardea Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 001-33734 94-3200380 (State or other jurisdicti
May 9, 2011	EX-10.1	EXECUTIVE EMPLOYMENT AGREEMENT EX-10.1 2 a59453exv10w1.htm EX-10.1 Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement”) is made and entered into effective as of February 28, 2011 (the “Effective Date”), by and between Ardea Biosciences, Inc. (the “Company”) and David T. Hagerty, MD (the “Executive”). The Company and the Executive are hereinafter collectively referred to as the “Parties”, and i
May 9, 2011	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q e10vq Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2011 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-33734 ARDEA BIOSCIENCES, INC.
April 12, 2011	DEFR14A	SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant þ Filed by a Party other than the Registrant o defr14a Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.
April 11, 2011	DEF 14A	SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant o def14a Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material Pursuant to § 240.
April 8, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2011 Ardea Biosciences, e8vk UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2011 Ardea Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-33734 94-3200380 (State or other jurisdiction of incorporation) (Commissio
March 11, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2011 Ardea Biosciences, e8vk Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 11, 2011	EX-10.8	ARDEA BIOSCIENCES, INC. 2000 EMPLOYEE STOCK PURCHASE PLAN Approved by the Board of Directors January 25, 2000 Approved by Stockholders February 25, 2000 Revised by Board of Directors October 8, 2007 EX-10.8 2 a58942exv10w8.htm EX-10.8 Exhibit 10.8 ARDEA BIOSCIENCES, INC. 2000 EMPLOYEE STOCK PURCHASE PLAN Approved by the Board of Directors January 25, 2000 Approved by Stockholders February 25, 2000 Revised by Board of Directors October 8, 2007 1. Purpose. (a) The purpose of this 2000 Employee Stock Purchase Plan (the “Plan”) is to provide a means by which employees of Ardea Biosciences, Inc. (
March 11, 2011	EX-99.1	Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results exv99w1 Exhibit 99.1 Contact: John Beck Ardea Biosciences, Inc. (858) 652-6523 [email protected] Ardea Biosciences Reports Recent Accomplishments and Announces Fourth Quarter and Full-Year 2010 Financial Results SAN DIEGO, March 11, 2011 — Ardea Biosciences, Inc. (Nasdaq: RDEA), a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases
March 11, 2011	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2010 or o TRANSITION REPORT PUR 10-K 1 a58942e10vk.htm FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2010 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from
February 14, 2011	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 5)* Ardea Biosciences, Inc. (Name of Issuer) Common Shares, no par value (Title of Class of Securities) 03969P107 (CUSIP N SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
February 11, 2011	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Ardea Biosciences (Name of Issuer) COMMON STOCK, $.001 PER SHARE (Title of Class of Securities) (CUSIP Number) Decembe Schedule 13G Amendment No. 3 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3)* Ardea Biosciences (Name of Issuer) COMMON STOCK, $.001 PER SHARE (Title of Class of Securities) 03969P107 (CUSIP Number) December 31, 2010 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the r
January 24, 2011	SC 13D/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 9)* UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.
January 24, 2011	SC 13D/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 8)* ARDEA BIOSCIENCES, INC. (Name of Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 8)* ARDEA BIOSCIENCES, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 03969P107 (CUSIP Number) Kevin C. Tang Tang Capital Management, LLC 4401 Eastgate Mall San Diego, CA 92121 (858) 200-3830 (Name, Address an
January 21, 2011	EX-99.1	ARDEA BIOSCIENCES PRICES PUBLIC OFFERING OF COMMON STOCK Exhibit 99.1 Contact: John Beck Ardea Biosciences, Inc. (858) 652-6523 [email protected] ARDEA BIOSCIENCES PRICES PUBLIC OFFERING OF COMMON STOCK SAN DIEGO—January 20, 2011—Ardea Biosciences, Inc. (NASDAQ: RDEA) today announced the pricing of a previously announced underwritten public offering of 2,750,000 shares of its common stock, offered at a price to the public of $26.00 per share. The gross
January 21, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 20, 2011 Ardea Bioscience e8vk Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
January 21, 2011	EX-1.1	2,750,000 Shares ARDEA BIOSCIENCES, INC. Common Stock ($0.001 par value per Share) UNDERWRITING AGREEMENT Exhibit 1.1 EXECUTION COPY 2,750,000 Shares ARDEA BIOSCIENCES, INC. Common Stock ($0.001 par value per Share) UNDERWRITING AGREEMENT January 20, 2011 Merrill Lynch, Pierce, Fenner & Smith Incorporated Jefferies & Company, Inc. as Representatives of the several Underwriters c/o Merrill Lynch, Pierce, Fenner & Smith Incorporated One Bryant Park New York, New York 10036 Ladies and Gentlemen: Introduc
January 21, 2011	424B5	2,750,000 Shares Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-170105 PROSPECTUS SUPPLEMENT (to Prospectus dated November 15, 2010) 2,750,000 Shares Common Stock We are selling 2,750,000 shares of our common stock. Our shares trade on The NASDAQ Global Select Market under the symbol “RDEA.” On January 19, 2011, the last sale price of the shares as reported on The NASDAQ Global Select Mark
January 19, 2011	424B5	Subject to Completion Preliminary Prospectus Supplement dated January 19, 2011 e424b5 Table of Contents The information contained in this prospectus supplement is not complete and may be changed.
January 19, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2011 Ardea Bioscience e8vk Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
January 10, 2011	EX-99.1	Ardea Biosciences Earns $15 Million Payment from Bayer HealthCare AG for Achievement of Important Clinical Milestone in Ongoing Collaboration Bayer Advances BAY 86-9766 into Phase 2 Clinical Trial for Liver Cancer exv99w1 Exhibit 99.1 Contact: John Beck Ardea Biosciences, Inc. (858) 652-6523 [email protected] Ardea Biosciences Earns $15 Million Payment from Bayer HealthCare AG for Achievement of Important Clinical Milestone in Ongoing Collaboration Bayer Advances BAY 86-9766 into Phase 2 Clinical Trial for Liver Cancer SAN DIEGO, January 10, 2011 — Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced tha
January 10, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2011 Ardea Bioscience e8vk Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
January 6, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 6, 2011 Ardea Biosciences e8vk Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
January 6, 2011	EX-99.2	EX-99.2 Exhibit 99.2 Ardea Biosciences Company Update January 6, 2011 Safe Harbor Statement Statements contained in this presentation regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expre
January 6, 2011	EX-99.1	Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients Adding RDEA594 to Allopurinol Achieved Up to 89% Response Rate in Patients Who Failed to Achieve Target Response exv99w1 Exhibit 99.1 Ardea John Beck Contact: Ardea Biosciences, Inc. (858) 652-6523 [email protected] Ardea Biosciences Announces Positive Top-Line Results from Phase 2b Combination Study of RDEA594 in Allopurinol-Refractory Gout Patients Adding RDEA594 to Allopurinol Achieved Up to 89% Response Rate in Patients Who Failed to Achieve Target Response on Allopurinol Alone Conference Call and Webca
December 21, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2010 Ardea Bioscienc e8vk Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 18, 2010	EX-99.1	A Multi-Center Phase 1, Dose —Escalation Trial to Determine the Safety and Pharmacokinetics/Pharmacodynamics of BAY 86-9766 (RDEA119), a MEK Inhibitor, in Advanced Cancer Patients C. D. Weekes1, D. D. Von Hoff2, A. A. Adjei3, L. Yeh4 , D. Leffingwell Exhibit 99.1 Poster #109 A Multi-Center Phase 1, Dose —Escalation Trial to Determine the Safety and Pharmacokinetics/Pharmacodynamics of BAY 86-9766 (RDEA119), a MEK Inhibitor, in Advanced Cancer Patients C. D. Weekes1, D. D. Von Hoff2, A. A. Adjei3, L. Yeh4 , D. Leffingwell 4, B. Sheedy4, C. Iverson4, P. Rajagopalan5, R. Dubowy5, N. Clendeninn4 1University of Colorado Cancer Center, Aurora, CO; 2
November 18, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2010 Ardea Bioscienc e8vk Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 17, 2010	424B3	$100,000,000 Ardea Biosciences, Inc. Common Stock Warrants Units e424b3 Table of Contents This filing is made pursuant to Rule 424(b)(3) under the Securities Act of 1933 in connection with Registration No.
November 9, 2010	EX-99.1	Ardea Biosciences Reports Recent Accomplishments and Third Quarter and Year-to-Date 2010 Financial Results Enrollment Completed in Phase 2b Study Evaluating RDEA594 Added to Allopurinol in Gout Patients Not Adequately Responding to Allopurinol Alone exv99w1 Exhibit 99.1 Ardea John Beck Contact: Ardea Biosciences, Inc. (858) 652-6523 [email protected] Ardea Biosciences Reports Recent Accomplishments and Third Quarter and Year-to-Date 2010 Financial Results Enrollment Completed in Phase 2b Study Evaluating RDEA594 Added to Allopurinol in Gout Patients Not Adequately Responding to Allopurinol Alone SAN DIEGO, November 9, 2010 — Ardea Bioscience
November 9, 2010	EX-10.1	Ardea Biosciences Inc. 2004 Stock Incentive Plan Stock Issuance Agreement EX-10.1 2 a57772exv10w1.htm EX-10.1 Exhibit 10.1 Ardea Biosciences Inc. 2004 Stock Incentive Plan Stock Issuance Agreement This Stock Issuance Agreement (the “Agreement”) is entered into as of [ ] 20, between Ardea Biosciences Inc., a Delaware corporation (the “Company”), and (the “Executive”). Whereas, the Company has employed the Executive pursuant to the terms of that certain Executive Employme
November 9, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2010 Ardea Bioscience e8vk Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 9, 2010	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2010 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-33734 ARDEA BIOSCIENCES, INC.
November 8, 2010	EX-99.2	Drug Candidate Event Date Gout Gout Gout RDEA594 Phase 2a - Cohort 2 Allopurinol Combo Results (Study 201) ? RDEA594 Febuxostat Combination Study Results (Study 105) ? RDEA594 Phase 2b Monotherapy Study Results (Study 202) ? RDEA594 Phase 2b Allopuri Exhibit 99.2 Drug Candidate Event Date Gout Gout Gout RDEA594 Phase 2a - Cohort 2 Allopurinol Combo Results (Study 201) ? RDEA594 Febuxostat Combination Study Results (Study 105) ? RDEA594 Phase 2b Monotherapy Study Results (Study 202) ? RDEA594 Phase 2b Allopurinol Add-On Study Results (Study 203) 2H10 RDEA594 Renal Impairment Study Results (Study 204) ? RDEA594 Phase 1b Allopurinol combination (
November 8, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2010 Ardea Bioscience e8vk Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 8, 2010	EX-99.1	Ardea Biosciences Announces Positive Results for RDEA594 in Combination with Febuxostat or Allopurinol in Gout Patients 100% Response Rate Achieved with All Doses of RDEA594 Combined with Febuxostat or Allopurinol; Serum Uric Acid Levels Reduced by U exv99w1 Exhibit 99.1 Contact: John Beck Ardea Biosciences, Inc. (858) 652-6523 [email protected] Ardea Biosciences Announces Positive Results for RDEA594 in Combination with Febuxostat or Allopurinol in Gout Patients 100% Response Rate Achieved with All Doses of RDEA594 Combined with Febuxostat or Allopurinol; Serum Uric Acid Levels Reduced by Up to 80% Company to Host Webcast at 8:30 PM Eastern
October 22, 2010	S-3	As filed with the Securities and Exchange Commission on October 22, 2010 Table of Contents As filed with the Securities and Exchange Commission on October 22, 2010 Registration No.
October 22, 2010	EX-4.4	ARDEA BIOSCIENCES, INC. and , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT EXHIBIT 4.4 ARDEA BIOSCIENCES, INC. and , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT ARDEA BIOSCIENCES, INC. COMMON STOCK WARRANT AGREEMENT COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of between ARDEA BIOSCIENCES, INC., a Delaware corporation (the “Company”) and, a [corporation] [national banking association] organized and existing under the laws of and having a corpor
October 22, 2010	EX-16.1	Los Angeles Orange County San Francisco East Bay Silicon Valley San Diego Hong Kong Exhibit 16.1 October 21, 2010 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7561 We have read Item 4.01 included in the Form 8-K/A of Ardea Biosciences, Inc. dated October 1, 2010 to be filed with the Securities and Exchange Commission. We agree with the statements concerning our Firm in such Form 8-K/A; we are not in a position to agree or disagree with other statem
October 22, 2010	8-K/A	Financial Statements and Exhibits, Changes in Registrant's Certifying Accountant Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2010 Ardea Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-33734 94-3200380 (State or other jurisdiction (Commission
October 7, 2010	EX-16.1	WWW.SJACCOUNTING.COM Los Angeles Orange County San Francisco East Bay Silicon Valley San Diego Hong Kong exv16w1 Exhibit 16.1 October 7, 2010 Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549-7561 We have read Item 4.01 included in the Form 8-K of Ardea Biosciences, Inc. dated October 1, 2010, to be filed with the Securities and Exchange Commission. We agree with the statements concerning our Firm in such Form 8-K; we are not in a position to agree or disagree with other st
October 7, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 1, 2010 Ardea Biosciences e8vk Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
September 17, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2010 Ardea Bioscien e8vk Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 10, 2010	SC 13G/A	By signing below, Prudential Financial, Inc. certifies that, to the best of its DOCUMENT TYPE SC 13G/A TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Amendment # 1 Name of Issuer: Ardea Biosciences, Inc. Title of Class of Securities: Common Stock CUSIP Number: 03969P107 1) NAME AND I.R.S. IDENTIFICATION NO. OF REPORTING PERSON Prudential Financial, Inc. 22-3703799 2.) MEMBER OF A GROUP: (a) N/A (b) N/A 3)
August 6, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2010 Ardea Biosciences, e8vk Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 6, 2010	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2010 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-33734 ARDEA BIOSCIENCES, INC.
August 6, 2010	EX-10.1	EXECUTIVE EMPLOYMENT AGREEMENT Exhibit 10.1 EXECUTIVE EMPLOYMENT AGREEMENT This Employment Agreement (the “Agreement") is made and entered into effective as of April 6, 2010 (the “Effective Date"), by and between Ardea Biosciences, Inc. (the “Company") and Stephen Davis (the “Executive"). The Company and the Executive are hereinafter collectively referred to as the “Parties", and individually referred to as a “Party". Recitals
August 6, 2010	EX-99.1	Ardea Biosciences Reports Recent Accomplishments and Second Quarter 2010 Financial Results exv99w1 Exhibit 99.1 Ardea John Beck Contact: Ardea Biosciences, Inc. (858) 652-6523 [email protected] Media Heidi Chokeir, Ph.D. Contact: Russo Partners, LLC (619) 528-2217 [email protected] Ardea Biosciences Reports Recent Accomplishments and Second Quarter 2010 Financial Results SAN DIEGO, August 6, 2010 — Ardea Biosciences, Inc. (Nasdaq: RDEA), a biotechnology company focused
June 18, 2010	EX-99.1	Positive Phase 2 Data on RDEA594, Ardea Biosciences’ Lead Product Candidate for the Treatment of Hyperuricemia and Gout, Presented at the Annual European Congress of Rheumatology New Data from Five Clinical Studies Reinforce RDEA594’s Robust Efficacy exv99w1 Exhibit 99.1 Ardea Contact: John Beck Ardea Biosciences, Inc. (858) 652-6523 [email protected] Media Contact: Heidi Chokeir, Ph.D. Russo Partners, LLC (619) 528-2217 [email protected] Positive Phase 2 Data on RDEA594, Ardea Biosciences’ Lead Product Candidate for the Treatment of Hyperuricemia and Gout, Presented at the Annual European Congress of Rheumatology New Data fr
June 18, 2010	EX-99.2	EX-99.2 exv99w2 Exhibit 99.2 EFFICACY AND SAFETY OF A RANGE OF DOSES OF RDEA594, A NOVEL URICOSURIC AGENT, AS MONOTHERAPY IN GOUT PATIENTS: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 EXPERIENCE F. Perez-Ruiz, V. Hingorani, J. Welp, B. Sheedy, K. Manhard, Z. Shen, J. Miner, M. Nguyen, D. Wilson, L. Yeh, B. Quart Annual European Congress of Rheumatology EULAR 2010 16-19 June 2010 Rome Disclosures
June 18, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2010 Ardea Biosciences, e8vk Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 27, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2010 Ardea Biosciences, I e8vk UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2010 Ardea Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-33734 94-3200380 (State or other jurisdiction of incorporation) (Commission
May 10, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2010 Ardea Biosciences, I e8vk Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 10, 2010	EX-99.1	EX-99.1 Exhibit 99.1 Company Update May 10, 2010 Safe Harbor Statement Statements contained in this presentation regarding matters that are not historical facts are "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by s
May 7, 2010	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 e10vq Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2010 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-33734 ARDEA BIOSCIENCES, INC.
May 7, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2010 Ardea Biosciences, In e8vk UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 7, 2010 Ardea Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorporation) 1-33734 (Commission File Number
May 7, 2010	EX-99.1	Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2010 Financial Results exv99w1 Exhibit 99.1 Ardea John Beck Contact: Ardea Biosciences, Inc. (858) 652-6523 [email protected] Media Contact: Heidi Chokeir, Ph.D. Russo Partners, LLC (619) 528-2217 [email protected] Ardea Biosciences Reports Recent Accomplishments and Announces First Quarter 2010 Financial Results SAN DIEGO, May 7, 2010 — Ardea Biosciences, Inc. (Nasdaq: RDEA) a biotechnology company fo
April 19, 2010	SC 13D/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 7 )* ARDEA BIOSCIENCES, INC. (Name of Issuer) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 7 )* ARDEA BIOSCIENCES, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 03969P107 (CUSIP Number) Kevin C. Tang Tang Capital Management, LLC 4401 Eastgate Mall San Diego, CA 92121 (858) 200-3830 (Name, Address a
April 16, 2010	DEF 14A	SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant o def14a Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material Pursuant to § 240.
April 9, 2010	EX-99.2	Ardea Biosciences, Inc. Announces Completion of Public Offering of Common Stock exv99w2 Exhibit 99.2 Ardea Biosciences, Inc. Announces Completion of Public Offering of Common Stock SAN DIEGO, April 9, 2010 /PRNewswire via COMTEX/ —Ardea Biosciences, Inc. (NASDAQ: RDEA) today announced the completion of a public offering of 4,025,000 shares of its common stock, including 525,000 shares sold pursuant to the full exercise of an overallotment option previously granted to the unde
April 9, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2010 Ardea Biosciences, e8vk UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 6, 2010 Ardea Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-33734 94-3200380 (State or other jurisdiction of incorporation) (Commissio
April 9, 2010	EX-1.1	3,500,000 Shares ARDEA BIOSCIENCES, INC. Common Stock ($0.001 par value per Share) UNDERWRITING AGREEMENT Exhibit 1.1 3,500,000 Shares ARDEA BIOSCIENCES, INC. Common Stock ($0.001 par value per Share) UNDERWRITING AGREEMENT April 6, 2010 JEFFERIES & COMPANY, INC. As Representative of the several Underwriters c/o JEFFERIES & COMPANY, INC. 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Introductory. Ardea Biosciences, Inc., a Delaware corporation (the “Company”), proposes to issue and
April 9, 2010	EX-99.1	Ardea Biosciences, Inc. Announces Pricing of Public Offering of Common Stock Exhibit 99.1 Ardea Biosciences, Inc. Announces Pricing of Public Offering of Common Stock SAN DIEGO, April 6, 2010 /PRNewswire via COMTEX/ —Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced the pricing of a public offering of 3,500,000 shares of its common stock. The offering is expected to close on or about April 9, 2010, subject to customary closing conditions. In addition, Ardea Bioscience
April 8, 2010	SC 13D/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 8)* Ardea Biosciences, Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Secur UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.
April 7, 2010	424B5	3,500,000 Shares Common Stock Table of Contents Filed Pursuant to Rule 424(b)5 Registration Statement No. 333-159279 Prospectus Supplement (to Prospectus dated June 5, 2009) 3,500,000 Shares Common Stock We are offering 3,500,000 shares of our common stock. Our common stock is quoted on The NASDAQ Global Market under the symbol “RDEA”. The last reported sale price of our common stock on The NASDAQ Global Market on April 5, 201
April 6, 2010	S-3MEF	As filed with the Securities and Exchange Commission on April 6, 2010 As filed with the Securities and Exchange Commission on April 6, 2010 Registration No.
April 5, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2010 Ardea Biosciences, e8vk UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2010 Ardea Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-33734 94-3200380 (State or other jurisdiction of incorporation) (Commissi
March 31, 2010	EX-99.1	Ardea Biosciences Announces Positive Top-Line Results from a Phase 2b Study of RDEA594 Given as Monotherapy in the Treatment of Hyperuricemia in Gout Patients RDEA594 Significantly Reduced Serum Urate Levels in Gout Patients and Was Well Tolerated Co exv99w1 Exhibit 99.1 Ardea John Beck Contact: Ardea Biosciences, Inc. (858) 652-6523 [email protected] Media Contact: Heidi Chokeir, Ph.D. Russo Partners, LLC (619) 528-2217 [email protected] Ardea Biosciences Announces Positive Top-Line Results from a Phase 2b Study of RDEA594 Given as Monotherapy in the Treatment of Hyperuricemia in Gout Patients RDEA594 Significantly Reduced S
March 31, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2010 Ardea Biosciences, e8vk UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2010 Ardea Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-33734 94-3200380 (State or other jurisdiction (Commission (IRS Employer o
March 12, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 12, 2010 Ardea Biosciences, e8vk Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 12, 2010	EX-10.10	ARDEA BIOSCIENCES, INC. 2004 STOCK INCENTIVE PLAN (As Amended and Restated Effective February 10, 2006) (As Amended December 21, 2006) (As Amended and Restated Effective June 29, 2007) (As Amended and Restated Effective December 16, 2009) ARTICLE ONE exv10w10 Exhibit 10.10 ARDEA BIOSCIENCES, INC. 2004 STOCK INCENTIVE PLAN (As Amended and Restated Effective February 10, 2006) (As Amended December 21, 2006) (As Amended and Restated Effective June 29, 2007) (As Amended and Restated Effective December 16, 2009) ARTICLE ONE GENERAL PROVISIONS I. PURPOSE OF THE PLAN This 2004 Stock Incentive Plan is intended to promote the interests of Ardea Bioscie
March 12, 2010	EX-99.1	Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance exv99w1 Exhibit 99.1 Ardea Contact: John Beck Ardea Biosciences, Inc. (858) 652-6523 [email protected] Media Heidi Chokeir, Ph.D. Contact: Russo Partners, LLC (619) 528-2217 [email protected] Ardea Biosciences Reports Recent Accomplishments; Provides 2010 Outlook; Announces Fourth Quarter and Full-Year 2009 Financial Results and 2010 Financial Guidance SAN DIEGO, March 12, 2010 —
March 12, 2010	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) þ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2009 or o TRANSITION REPORT PUR e10vk Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 8, 2010	EX-99.1	Summary Description of Ardea Biosciences, Inc. 2010 Executive Bonus Plan As of March 2, 2010 exv99w1 Exhibit 99.1 Summary Description of Ardea Biosciences, Inc. 2010 Executive Bonus Plan As of March 2, 2010 Eligibility: Generally, employees of Ardea Biosciences, Inc. with a title of Vice President or above are eligible to participate in the plan. Participants must be employed with Ardea Biosciences, Inc. on the day that bonuses are paid in order to be eligible for a bonus. Bonus Opportuni
March 8, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2010 Ardea Biosciences, e8vk UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2010 Ardea Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-33734 94-3200380 (State or other jurisdiction of incorporation) (Commissio
March 8, 2010	EX-99.2	Company Update March 8, 2010 exv99w2 Exhibit 99.2 Company Update March 8, 2010 Safe Harbor Statement Statements contained in this presentation regarding matters that are not historical facts are "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or imp
February 16, 2010	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ARDEA BIOSCIENCES, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Sec UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* ARDEA BIOSCIENCES, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 03969P107 (CUSIP Number) December 31, 2009 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the
February 12, 2010	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Ardea Biosciences (Name of issuer) COMMON STOCK, $.001 PER SHARE (Title of class of securities) (CUSIP number) Decembe Schedule 13G Amendment No. 2 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Ardea Biosciences (Name of issuer) COMMON STOCK, $.001 PER SHARE (Title of class of securities) 03969P107 (CUSIP number) December 31, 2009 (Date of event which requires filing of this statement) Check the appropriate box to designate the r
February 12, 2010	SC 13G	By signing below, Prudential Financial, Inc. certifies that, to the best of its DOCUMENT TYPE SC 13G TEXT SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Name of Issuer: Ardea Biosciences, Inc. Title of Class of Securities: Common Stock CUSIP Number: 03969P107 1) NAME AND I.R.S. IDENTIFICATION NO. OF REPORTING PERSON Prudential Financial, Inc. 22-3703799 2.) MEMBER OF A GROUP: (a) N/A (b) N/A 3) SEC USE ONLY: 4)
February 12, 2010	SC 13G/A	SECURITIES AND EXCHANGE COMMISSION SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No.
February 12, 2010	SC 13D/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 7)* Ardea Biosciences, Inc. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Secur UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.
February 9, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2010 Ardea Bioscience e8vk UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2010 Ardea Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-33734 94-3200380 (State or other jurisdiction of incorporation) (Commis
February 9, 2010	EX-99.1	Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors exv99w1 Exhibit 99.1 PRESS RELEASE Ardea Contact: John Beck Ardea Biosciences, Inc. (858) 652-6523 [email protected] Media Contact: Heidi Chokeir, Ph.D. Russo Partners, LLC (619) 528-2217 [email protected] Ardea Biosciences Announces Appointment of Felix J. Baker, Ph.D. to Board of Directors SAN DIEGO, February 9, 2010 — Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that
January 11, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2010 Ardea Bioscience e8vk Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
January 11, 2010	EX-99.1	EX-99.1 exv99w1 Exhibit 99.1 Company Update January 11, 2010 Safe Harbor Statement Statements contained in this presentation regarding matters that are not historical facts are "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or
January 7, 2010	EX-99.1	Ardea Biosciences Reports Positive Results for RDEA594, its Lead Product Candidate for Gout, in Combination with Allopurinol or Febuxostat - 100% of patients reached target serum urate levels with the combination of RDEA594 and allopurinol - RDEA594 exv99w1 Exhibit 99.1 Ardea John Beck Contact: Ardea Biosciences, Inc. (858) 652-6523 [email protected] Media Heidi Chokeir, Ph.D. Contact: Russo Partners, LLC (619) 528-2217 [email protected] Ardea Biosciences Reports Positive Results for RDEA594, its Lead Product Candidate for Gout, in Combination with Allopurinol or Febuxostat - 100% of patients reached target serum urate level
January 7, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2010 Ardea Biosciences e8vk UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 7, 2010 Ardea Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-33734 94-3200380 (State or other jurisdiction (Commission (IRS Employer
December 22, 2009	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2009 Ardea Bioscienc e8vk UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2009 Ardea Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-33734 94-3200380 (State or other jurisdiction of incorporation) (Commi
December 16, 2009	CORRESP	4939 Directors Place, San Diego, CA 92121 Tel (858)652-6500 Fax (858) 625-0745 www.ardeabio.com corresp VIA U.S. MAIL AND EDGAR December 16, 2009 Jeffrey P. Riedler Assistant Director Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Mail Stop 3030 Washington, D.C. 20549 Re: Ardea Biosciences, Inc. Form 10-K for the year ended December 31, 2008 Filed March 13, 2009 File No. 001-33734 DEF14A Filed April 16, 2009 File No. 001-33734 Dear Mr. Riedler: Reference
December 1, 2009	EX-99.2	Ardea Biosciences Reports Positive Results from Combination of RDEA594 and Febuxostat Exhibit 99.2 PRESS RELEASE Ardea John Beck Contact: Ardea Biosciences, Inc. (858) 652-6523 [email protected] Media Heidi Chokeir, Ph.D. Contact: Russo Partners, LLC (619) 528-2217 [email protected] Ardea Biosciences Reports Positive Results from Combination of RDEA594 and Febuxostat SAN DIEGO, December 1, 2009 — Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced positive resu
December 1, 2009	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2009 Ardea Bioscience e8vk Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
December 1, 2009	EX-99.1	EX-99.1 Exhibit 99.1 Company Update December 1, 2009 Safe Harbor Statement Statements contained in this presentation regarding matters that are not historical facts are "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied
November 6, 2009	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 6, 2009 Ardea Bioscience e8vk Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
November 6, 2009	EX-99.1	Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results exv99w1 Exhibit 99.1 PRESS RELEASE Contact: John Beck Ardea Biosciences, Inc. (858) 652-6523 [email protected] Media Contact: Heidi Chokeir, Ph.D. Russo Partners, LLC (619) 528-2217 [email protected] Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financial Results SAN DIEGO, November 6, 2009 — Ardea Biosciences, Inc. (Nasdaq: RD
November 6, 2009	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2009 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-33734 ARDEA BIOSCIENCES, INC.
November 3, 2009	EX-99.1	Company Update November 3, 2009 exv99w1 Exhibit 99.1 Company Update November 3, 2009 Safe Harbor Statement Statements contained in this presentation regarding matters that are not historical facts are "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or
November 3, 2009	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 2, 2009 Ardea Bioscience e8vk Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
October 23, 2009	CORRESP	4939 Directors Place, San Diego, CA 92121 Tel (858)652-6500 Fax (858) 625-0745 www.ardeabio.com corresp VIA U.S. MAIL AND EDGAR October 23, 2009 Jeffrey P. Riedler Assistant Director Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Mail Stop 3030 Washington, D.C. 20549 Re: Ardea Biosciences, Inc. Form 10-K for the year ended December 31, 2008 Filed March 13, 2009 File No. 001-33734 DEF14A Filed April 16, 2009 File No. 001-33734 Dear Mr. Riedler: On behalf
October 19, 2009	EX-99.1	EX-99.1 EX-99.1 2 a54060exv99w1.htm EX-99.1 Exhibit 99.1 Company Update October 19, 2009 Safe Harbor Statement Statements contained in this presentation regarding matters that are not historical facts are "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materia
October 19, 2009	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2009 Ardea Bioscience e8vk Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
October 19, 2009	EX-99.2	Ardea Biosciences Announces Additional Positive Results from a Phase 2a Study of RDEA594 at the 2009 ACR/ARHP Annual Scientific Meeting RDEA594 Significantly Reduced Serum Urate Levels in Gout Patients and Was Well Tolerated Conference Call and Webca exv99w2 Exhibit 99.2 DRAFT Ardea Contact: John Beck Ardea Biosciences, Inc. (858) 652-6523 [email protected] Media Contact: Heidi Chokeir, Ph.D. Russo Partners, LLC (619) 528-2217 [email protected] Ardea Biosciences Announces Additional Positive Results from a Phase 2a Study of RDEA594 at the 2009 ACR/ARHP Annual Scientific Meeting RDEA594 Significantly Reduced Serum Urate Levels
September 11, 2009	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 11, 2009 Ardea Bioscien e8vk Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
September 11, 2009	EX-99.1	EX-99.1 exv99w1 Exhibit 99.1 Company Update September 11, 2009 Safe Harbor Statement Statements contained in this presentation regarding matters that are not historical facts are "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed o
September 10, 2009	CORRESP	Re: Ardea Biosciences, Inc. Form 10-K for the year ended December 31, 2008 Filed March 13, 2009 File No. 001-33734 DEF14A Filed April 16, 2009 File No. 001-33734 FORM CORRESP VIA U.S. MAIL AND EDGAR September 10, 2009 Jeffrey P. Riedler Assistant Director Securities and Exchange Commission Division of Corporation Finance 100 F Street N.E. Mail Stop 3030 Washington, D.C. 20549 Re: Ardea Biosciences, Inc. Form 10-K for the year ended December 31, 2008 Filed March 13, 2009 File No. 001-33734 DEF14A Filed April 16, 2009 File No. 001-33734 Dear Mr. Riedler: On
August 7, 2009	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2009 Ardea Biosciences, e8vk Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
August 7, 2009	EX-10.1	DEVELOPMENT AND COMMERCIALIZATION LICENSE AGREEMENT Exhibit 10.1 *** Text omitted and Filed Separately CONFIDENTIAL TREATMENT REQUESTED Under C.F.R. §§200.80(b)(4) and 240.24b-2 DEVELOPMENT AND COMMERCIALIZATION LICENSE AGREEMENT This Development and Commercialization License Agreement (the “Agreement”), is entered into as of April 27, 2009 (the “Signing Date”) by and between Ardea Biosciences, Inc., a Delaware corporation, having an address of 493
August 7, 2009	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2009 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-33734 ARDEA BIOSCIENCES, INC.
August 7, 2009	EX-99.1	Ardea Biosciences Reports Recent Accomplishments and Announces Second Quarter and Year-to-Date 2009 Financial Results exv99w1 Exhibit 99.1 PRESS RELEASE Contact: John Beck Ardea Biosciences, Inc. (858) 652-6523 [email protected] Media Heidi Chokier, Ph.D. Contact: Russo Partners, LLC (619) 528-2217 [email protected] Ardea Biosciences Reports Recent Accomplishments and Announces Second Quarter and Year-to-Date 2009 Financial Results SAN DIEGO, August 7, 2009 — Ardea Biosciences, Inc. (Nasdaq: RDE
July 31, 2009	424B3	PROSPECTUS SUPPLEMENT No. 2 (TO PROSPECTUS DATED JANUARY 20, 2009) Filed Pursuant to Rule 424(b)(3) under the Securities Act of 1933 in connection with Registration No. 333-156708 ARDEA BIOSCIENCES, INC. COMMON STOCK e424b3 PROSPECTUS SUPPLEMENT No. 2 (TO PROSPECTUS DATED JANUARY 20, 2009) Filed Pursuant to Rule 424(b)(3) under the Securities Act of 1933 in connection with Registration No. 333-156708 ARDEA BIOSCIENCES, INC. COMMON STOCK This prospectus supplement No. 2 supplements and amends the prospectus dated January 20, 2009, as supplemented, which is referred to herein as the Prior Prospectus, relating to
June 11, 2009	EX-99.1	Ardea Biosciences Announces Positive Interim Phase 2a Results for Lead Gout Drug, RDEA594 86% Response Rate in Gout Patients After Eight Days of Treatment exv99w1 Exhibit 99.1 PRESS RELEASE Contact: John Beck Ardea Biosciences, Inc. (858) 652-6523 [email protected] Ardea Biosciences Announces Positive Interim Phase 2a Results for Lead Gout Drug, RDEA594 86% Response Rate in Gout Patients After Eight Days of Treatment SAN DIEGO, June 11, 2009 — Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced positive interim results from an ongoing Phase 2a,
June 11, 2009	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2009 Ardea Biosciences, e8vk UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 11, 2009 Ardea Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-33734 94-3200380 (State or other jurisdiction (Commission (IRS Employer of
June 11, 2009	EX-99.2	EX-99.2 Exhibit 99.2 Company Update June 11, 2009 Safe Harbor Statement Statements contained in this presentation regarding matters that are not historical facts are "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by
June 5, 2009	424B3	$75,000,000 Ardea Biosciences, Inc. Common Stock e424b3 Table of Contents This filing is made pursuant to Rule 424(b)(3) under the Securities Act of 1933 in connection with Registration No.
May 15, 2009	S-3	As filed with the Securities and Exchange Commission on May 15, 2009 sv3 Table of Contents As filed with the Securities and Exchange Commission on May 15, 2009 Registration No.
May 11, 2009	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2009 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-33734 ARDEA BIOSCIENCES, INC.
May 8, 2009	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2009 Ardea Biosciences, In e8vk Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
May 8, 2009	EX-99.1	Ardea Biosciences Reports Recent Accomplishments and First Quarter 2009 Financial Results Restructuring to Focus Company on Clinical-Stage Programs exv99w1 Exhibit 99.1 PRESS RELEASE Contact: John Beck Ardea Biosciences, Inc. (858) 652-6523 [email protected] Ardea Biosciences Reports Recent Accomplishments and First Quarter 2009 Financial Results Restructuring to Focus Company on Clinical-Stage Programs SAN DIEGO, May 8, 2009 — Ardea Biosciences, Inc. (Nasdaq: RDEA), a biotechnology company focused on the development of small-molecule therap
May 1, 2009	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2009 Ardea Biosciences, e8vk UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 27, 2009 Ardea Biosciences, Inc. (Exact name of registrant as specified in its charter) Delaware 1-33734 94-3200380 (State or other jurisdiction of incorporation) (Commissi
May 1, 2009	EX-99.1	Ardea Biosciences and Bayer HealthCare Enter into Global Agreement Focused on the Development of MEK Inhibitors for the Treatment of Cancer exv99w1 Exhibit 99.1 PRESS RELEASE Contact: John Beck Ardea Biosciences, Inc. (858) 652-6523 [email protected] Ardea Biosciences and Bayer HealthCare Enter into Global Agreement Focused on the Development of MEK Inhibitors for the Treatment of Cancer SAN DIEGO, April 28, 2009 — Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced that it has entered into a global agreement with Bayer HealthCare
April 20, 2009	EX-99.2	Ardea Biosciences Announces Positive Results from a Phase 1 Study of Lead Hyperuricemia and Gout Candidate, RDEA594 and a Phase 2a Study of RDEA594’s Prodrug, RDEA806 exv99w2 Exhibit 99.2 PRESS RELEASE Contact: John Beck Ardea Biosciences, Inc. (858) 652-6523 [email protected] Ardea Biosciences Announces Positive Results from a Phase 1 Study of Lead Hyperuricemia and Gout Candidate, RDEA594 and a Phase 2a Study of RDEA594’s Prodrug, RDEA806 SAN DIEGO, April 20, 2009 — Ardea Biosciences, Inc. (Nasdaq: RDEA) today announced positive results from a Phase 1 study
April 20, 2009	EX-99.1	EX-99.1 Exhibit 99.1 Investor and Analyst Event April 20, 2009 Safe Harbor Statement Statements contained in this presentation regarding matters that are not historical facts are "forward- looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed o
April 20, 2009	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2009 Ardea Biosciences, e8vk Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 16, 2009	DEF 14A	SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant o def14a Table of Contents SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant þ Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) þ Definitive Proxy Statement o Definitive Additional Materials o Soliciting Material Pursuant to § 240.
April 14, 2009	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 7, 2009 Ardea Biosciences, e8vk Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 14, 2009	EX-99.1	Summary Description of Ardea Biosciences, Inc. 2009 Executive Bonus Plan As of April 7, 2009 exv99w1 Exhibit 99.1 Summary Description of Ardea Biosciences, Inc. 2009 Executive Bonus Plan As of April 7, 2009 Eligibility: All employees of Ardea Biosciences, Inc. with a title of Vice President or above are eligible to participate in the plan. Participants must be employed with Ardea Biosciences, Inc. on the day that bonuses are paid in order to be eligible for a bonus. Bonus Opportunity: The
April 9, 2009	S-8	As filed with the Securities and Exchange Commission on April 9, 2009 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Ardea Biosciences, In Table of Contents As filed with the Securities and Exchange Commission on April 9, 2009 Registration No.

RDEA / Ardea Biosciences, Inc. - SEC-arkivering, Årsberetning, Fuldmagtserklæring

Grundlæggende statistik

SEC Filings

SEC Filings (Chronological Order)